HOME > BUSINESS
BUSINESS
- Ninlaro Meets Primary Endpoint as 1st-Line Maintenance Therapy for Multiple Myeloma: Takeda
November 11, 2019
- Nippon Kayaku Forecasts 4.3 Billion Yen Full-Year Sales for Biosimilars
November 11, 2019
- BI Japan and Nippon BI to Merge in January Next Year to Increase Management Efficiency
November 11, 2019
- China Emerges as a Key Destination for New Clinical Trials in 2018: Informa Report
November 8, 2019
- Japan Market Logs Hefty 8.9% Growth in July-September: IQVIA
November 8, 2019
- AstraZeneca’s COPD Triplet Promotion Stands Out in August: Impact Track
November 8, 2019
- Keytruda Stays on Top in October Japan Drug Ranking: Encise
November 8, 2019
- Takeda’s Dengue Vaccine Candidate Showed Confirmed Protection Efficacy in PIII
November 8, 2019
- As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company
November 7, 2019
- 3rd Conditional Approval Candidate Was DMD Drug Viltolarsen, Nippon Shinyaku Reveals
November 7, 2019
- Takeda Acquires Rights to CAR NK Cell Therapies from MD Anderson
November 7, 2019
- Takeda Opens New Dengue Vaccine Manufacturing Facility in Germany
November 7, 2019
- 8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Treakisym Succeeds in PIII DLBCL Study, Japan Filing Eyed in H1 2020: SymBio
November 6, 2019
- Takeda to Divest Non-Core Assets Sold in Russia, Former Soviet States
November 6, 2019
- Daiichi Sankyo Sues Seattle Genetics over ADC Technology
November 6, 2019
- Eisai Transfers Tazemetostat Royalty Rights Outside Japan to US Firm
November 6, 2019
- Crysvita Accepted for Review in Europe for Additional Adult Use
November 6, 2019
- Torii Acquires Japan Marketing Rights to BioCryst’s HAE Treatment
November 6, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
